FLASH NEWS LIVE

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Read Full Article →

Read more

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp